Lupin clears Japanese regulator PMDA inspection of Goa facility

The Pharmaceutical and Medical Devices Agency (PMDA), Japan, has completed the Good Manufacturing Practice inspection of the company's Goa facility (unit I and II), Lupin said in a filing to the BSE.

New Delhi: Drug firm Lupin on Monday said Japanese regulator PMDA has closed inspection of its Goa facility with no critical or major observations.

The Pharmaceutical and Medical Devices Agency (PMDA), Japan, has completed the Good Manufacturing Practice inspection of the company's Goa facility (unit I and II), Lupin said in a filing to the BSE.

Also Read: Lupin unveils a generic version of Viagra in the US

The inspection was conducted between September 24 and 27, it added. "The PMDA inspection closed with no critical or major observations," Lupin said.

According to PMDA, its obligation is to protect the public health in Japan by assuring safety, efficacy and quality of pharmaceuticals and medical devices.

Based in Mumbai, Lupin is a player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-Infective and NSAI D space and holds a global leadership position in the AntiTB segment.

Also Read: Lupin ropes in Jon Stelzmiller to head US speciality business